Literature DB >> 10935983

Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.

E Beirnaert1, P Nyambi, B Willems, L Heyndrickx, R Colebunders, W Janssens, G van der Groen.   

Abstract

A previous study on cross-clade neutralization activity, identified three key isolates, MNlab (envB/gagB; X4 coreceptor), VI525 (envG/gagH, envA/gagA; R5X4) and CA9 (Group O; R5), that allowed discrimination of sera, likely or unlikely to neutralize primary HIV-1 isolates belonging to Group M (env clades A-H) and Group O. The prognostic ability of these three isolates was verified by means of an external validation on a different and larger set of sera. A total of 79 different sera (66 HIV-1, 10 HIV-2, 1 HIV-1+2 and 2 SIV(cpz)) were examined first for their capacity to neutralize the three key isolates, next sera were challenged against 12 other primary HIV-1 isolates of Group M (env A-H) and 2 isolates of Group O. Sera that neutralized all three isolates with an ID(50) titer of > or =1/40, also neutralized the 14 other primary isolates belonging to different genetic groups and clades. Sera that did not neutralize all three isolates did not exert broad cross-neutralizing activity. The neutralizing activity was antibody-mediated because it was absorbed and eluted from a Prot-G column. Competition-neutralization experiments using recombinant gp120 (HIV-1 MNlab) reduced the neutralizing capacity, suggesting that the neutralizing antibodies were directed against the Env protein. Remarkably, the broad cross-neutralization activity was found primarily in African female patients. In conclusion, this study confirms that three isolates are sufficient to allow identification of broad cross-neutralizing sera. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935983

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  26 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques.

Authors:  Francois Villinger; Ann E Mayne; Pavel Bostik; Kazuyasu Mori; Peter E Jensen; Rafi Ahmed; Aftab A Ansari
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Authors:  Nicole A Doria-Rose
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

4.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

6.  Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.

Authors:  M Medina-Ramírez; V Sánchez-Merino; S Sánchez-Palomino; A Merino-Mansilla; C B Ferreira; I Pérez; N González; A Alvarez; J M Alcocer-González; F García; J M Gatell; J Alcamí; E Yuste
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

7.  B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.

Authors:  Saikat Boliar; Megan K Murphy; T Cameron Tran; Diane G Carnathan; Wendy S Armstrong; Guido Silvestri; Cynthia A Derdeyn
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

8.  Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination.

Authors:  Samer Sourial; Anette Wärnmark; Charlotta Nilsson; Ewa Björling; Adnane Achour; Robert A Harris
Journal:  Mol Biotechnol       Date:  2005-06       Impact factor: 2.695

9.  Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Marcus G Daniels; Sijy O'Dell; Martha Nason; Alan Lapedes; Tanmoy Bhattacharya; Stephen A Migueles; Richard T Wyatt; Bette T Korber; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

10.  Comparison of predicted scaffold-compatible sequence variation in the triple-hairpin structure of human imunodeficiency virus type 1 gp41 with patient data.

Authors:  Nathalie Boutonnet; Wouter Janssens; Carlo Boutton; Jean-Luc Verschelde; Leo Heyndrickx; Els Beirnaert; Guido van der Groen; Ignace Lasters
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.